PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Burosumab→

Burosumab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1610833-03-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Fully human monoclonal antibodyfibroblast growth factor 23 (FGF23) inhibitor
Mechanism of action
Binds FGF23 and inhibits its biological activity, restoring renal tubular phosphate reabsorption and increasing renal production of 1,25-dihydroxyvitamin D. This increases serum phosphate availability for bone mineralisation.
Indications / reported uses
  • Treatment of X-linked hypophosphataemia (XLH) in eligible adults and children aged 6 months and older, according to product-specific age and clinical criteria
  • Treatment of tumour-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised, in eligible adults and paediatric patients aged 2 years and older under the applicable US label

Sources: US FDA prescribing information — CRYSVITA, updated 2026 · EMA EPAR — Crysvita · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Burosumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Burosumab Permitted Daily Exposure (PDE) report (the Burosumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Burosumab Occupational Exposure Limit (OEL) report (the Burosumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.